Noetik Closes $40M Series A Financing to Advance AI-Driven Cancer Therapeutics
Noetik is dedicated to solving critical challenges in cancer treatment by leveraging cutting-edge AI and biotech innovations.
Company Name: Noetik
Location: San Francisco, CA
Sector: AI, Biotechnology, Cancer Therapeutics
Funding Details: Closed a $40 million Series A financing round led by Polaris Partners, with managing partner Amy Schulman joining the board of directors. The round also saw participation from new investors Khosla Ventures, Wittington Ventures, Breakout Ventures, and existing investors DCVC, Zetta Venture Partners, Catalio Capital Management, 11.2 Capital, Epic Ventures, Intermountain Ventures, and North South Ventures. Additional support came from AI funds ApSTAT Technologies, Linearis Labs, and Ventures Fund, backed by AI expert Yoshua Bengio, metabolomic expert David Wishart, Element AI co-founder Jean-Francois Gagne, and current and former Recursion executives.
Purpose of Investment: The company plans to use the funds to expand its spatial omics-based atlas of human cancer biology, along with its high-throughput in vivo CRISPR Perturb-Map platform. The investment will also support the scaling of training for its multi-modal cancer foundation models, such as OCTO.
Product and Innovation: Led by Ron Alfa, M.D., Ph.D., CEO & Co-Founder, Noetik is an AI-native biotech company focused on developing next-generation cancer therapeutics. The company pairs human multimodal spatial omics data, designed specifically for machine learning, with a massively multiplexed in vivo CRISPR perturbation platform (Perturb-Map). These combined data are used to train self-supervised foundation models of tissue and tumor biology, which drive the company’s discovery efforts to improve target discovery and biomarker development, ultimately increasing the probability of clinical success.
About the Company: Noetik is dedicated to solving critical challenges in cancer treatment by leveraging cutting-edge AI and biotech innovations. The company's platform aims to revolutionize the discovery and development of effective new therapeutics by enhancing the accuracy and efficiency of target discovery and biomarker development.
